AVITA Medical Announces FDA Approval Of RECELL For Skin Repigmentation In Vitiligo Patients
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical has received FDA approval for its RECELL System for the treatment of vitiligo, making it the first FDA-approved therapeutic device offering a one-time treatment at the point-of-care. The approval significantly expands the clinical applications for RECELL.
June 16, 2023 | 6:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AVITA Medical's FDA approval for its RECELL System for vitiligo treatment expands the clinical applications for the product, potentially increasing demand and revenue.
The FDA approval for AVITA Medical's RECELL System for vitiligo treatment is a significant milestone for the company. This approval expands the clinical applications for the product, which could lead to increased demand and revenue for the company. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100